Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.

@article{Mills2015TenofovirAV,
  title={Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.},
  author={Anthony Mills and Gordon Crofoot and Cheryl McDonald and Peter Shalit and Jason A Flamm and Joseph Clayton Gathe and Anita R Scribner and David Shamblaw and Michael Saag and Huyen L Cao and Hal David Martin and Moupali Das and Anne Thomas and Hui C. Liu and Mingjin Yan and Christian Callebaut and Joseph M. Custodio and Andrew Hua an Cheng and S Mccallister},
  journal={Journal of acquired immune deficiency syndromes},
  year={2015},
  volume={69 4},
  pages={439-45}
}
OBJECTIVES To evaluate the safety and efficacy of the novel tenofovir prodrug, tenofovir alafenamide (TAF), as part of the first protease inhibitor-based single-tablet regimen (STR) for initial treatment of HIV-1 infection. METHODS Antiretroviral therapy (ART)-naive adults with estimated glomerular filtration rate ≥ 70 mL/min were randomized 2:1 to receive the darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) STR (TAF: N = 103) or darunavir + cobicistat + emtricitabine… CONTINUE READING